
## Danyan Xu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8192610/publications.pdf Version: 2024-02-01



ΠΑΝΥΑΝ ΧΗ

#	Article	IF	CITATIONS
1	The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease. Cardiovascular Drugs and Therapy, 2022, 36, 263-269.	2.6	1
2	New insights into the roles of glucocorticoid signaling dysregulation in pathological cardiac hypertrophy. Heart Failure Reviews, 2022, 27, 1431-1441.	3.9	4
3	Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the "Prime Time―of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?. Cardiovascular Drugs and Therapy, 2021, 35, 467-477.	2.6	18
4	Circular RNA in cardiovascular disease: Expression, mechanisms and clinical prospects. Journal of Cellular and Molecular Medicine, 2021, 25, 1817-1824.	3.6	39
5	Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis. Medicine (United States), 2021, 100, e24579.	1.0	10
6	Advances in the mechanism and treatment of mitochondrial quality control involved in myocardial infarction. Journal of Cellular and Molecular Medicine, 2021, 25, 7110-7121.	3.6	3
7	Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis. Drugs, 2021, 81, 2003-2016.	10.9	2
8	Sex differences in survival after out-of-hospital cardiac arrest: a meta-analysis. Critical Care, 2020, 24, 613.	5.8	42
9	Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. Cardiovascular Diabetology, 2020, 19, 33.	6.8	26
10	Stable coronary artery disease and endothelial progenitor cells. International Journal of Cardiology, 2018, 260, 18.	1.7	2
11	Soluble epoxide hydrolase inhibitors might prevent ischemic arrhythmias via microRNA-1 repression in primary neonatal mouse ventricular myocytes. Molecular BioSystems, 2017, 13, 556-564.	2.9	9
12	Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1 and its target genes in myocardial infarction mice. Oncotarget, 2017, 8, 94635-94649.	1.8	14
13	Is sEHi lowering LDL-C by reducing expression of PCSK9 through SREBP2 pathway?. International Journal of Cardiology, 2016, 207, 361-362.	1.7	1
14	The S100A8-serum amyloid A3-LOX-1 cascade in atherosclerotic plaque rupture. International Journal of Cardiology, 2016, 203, 832-833.	1.7	3
15	RKIP corrects impaired beta (2)-adrenergic receptor vasodilatation in hypertension by downregulation of GRK2. International Journal of Cardiology, 2016, 207, 359-360.	1.7	3
16	Aerobic exercise-based rehabilitation affects the activities of progenitor endothelial cells through EETs pathway. Medical Hypotheses, 2015, 85, 1037-1038.	1.5	2
17	A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARÎ <sup>3</sup> to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. International Journal of Cardiology, 2013, 167, 1298-1304.	1.7	59
18	Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2010, 88, 71-75.	2.8	18

		Danyan Xu		
#	Article	IF	CITATIONS	
19	Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine. Atherosclerosis, 2010, 211, 237-241.	0.8	21	